89 related articles for article (PubMed ID: 28108288)
1. KLF4 expression enhances the efficacy of chemotherapy drugs in ovarian cancer cells.
Wang B; Shen A; Ouyang X; Zhao G; Du Z; Huo W; Zhang T; Wang Y; Yang C; Dong P; Watari H; Pfeffer LM; Yue J
Biochem Biophys Res Commun; 2017 Mar; 484(3):486-492. PubMed ID: 28108288
[TBL] [Abstract][Full Text] [Related]
2. Phase 1 study of APTO-253 HCl, an inducer of KLF4, in patients with advanced or metastatic solid tumors.
Cercek A; Wheler J; Murray PE; Zhou S; Saltz L
Invest New Drugs; 2015 Oct; 33(5):1086-92. PubMed ID: 26268924
[TBL] [Abstract][Full Text] [Related]
3. Krüppel-Like Factor 4 and Its Activator APTO-253 Induce NOXA-Mediated, p53-Independent Apoptosis in Triple-Negative Breast Cancer Cells.
Nakajima W; Miyazaki K; Asano Y; Kubota S; Tanaka N
Genes (Basel); 2021 Apr; 12(4):. PubMed ID: 33918002
[TBL] [Abstract][Full Text] [Related]
4. SIRT1 deacetylates KLF4 to activate Claudin-5 transcription in ovarian cancer cells.
Zhang X; Chen J; Sun L; Xu Y
J Cell Biochem; 2018 Feb; 119(2):2418-2426. PubMed ID: 28888043
[TBL] [Abstract][Full Text] [Related]
5. Doxycycline inducible Krüppel-like factor 4 lentiviral vector mediates mesenchymal to epithelial transition in ovarian cancer cells.
Chen Z; Wang Y; Liu W; Zhao G; Lee S; Balogh A; Zou Y; Guo Y; Zhang Z; Gu W; Li C; Tigyi G; Yue J
PLoS One; 2014; 9(8):e105331. PubMed ID: 25137052
[TBL] [Abstract][Full Text] [Related]
6. KLF4 sensitizes the colon cancer cell HCT-15 to cisplatin by altering the expression of HMGB1 and hTERT.
Yadav SS; Kumar M; Varshney A; Yadava PK
Life Sci; 2019 Mar; 220():169-176. PubMed ID: 30716337
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of glutathione synthesis reverses Krüppel-like factor 4-mediated cisplatin resistance.
Jia Y; Zhang W; Liu H; Peng L; Yang Z; Lou J
Cancer Chemother Pharmacol; 2012 Feb; 69(2):377-85. PubMed ID: 21833590
[TBL] [Abstract][Full Text] [Related]
8. Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer.
McEvoy LM; O'Toole SA; Spillane CD; Martin CM; Gallagher MF; Stordal B; Blackshields G; Sheils O; O'Leary JJ
BMC Cancer; 2015 Jul; 15():547. PubMed ID: 26205780
[TBL] [Abstract][Full Text] [Related]
9. APTO-253 Stabilizes G-quadruplex DNA, Inhibits MYC Expression, and Induces DNA Damage in Acute Myeloid Leukemia Cells.
Local A; Zhang H; Benbatoul KD; Folger P; Sheng X; Tsai CY; Howell SB; Rice WG
Mol Cancer Ther; 2018 Jun; 17(6):1177-1186. PubMed ID: 29626127
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic alterations of Krüppel-like factor 4 and its tumor suppressor function in renal cell carcinoma.
Li H; Wang J; Xiao W; Xia D; Lang B; Yu G; Guo X; Guan W; Wang Z; Hu Z; Liu J; Ye Z; Xu H
Carcinogenesis; 2013 Oct; 34(10):2262-70. PubMed ID: 23722653
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
12. Time-staggered inhibition of JNK effectively sensitizes chemoresistant ovarian cancer cells to cisplatin and paclitaxel.
Seino M; Okada M; Sakaki H; Takeda H; Watarai H; Suzuki S; Seino S; Kuramoto K; Ohta T; Nagase S; Kurachi H; Kitanaka C
Oncol Rep; 2016 Jan; 35(1):593-601. PubMed ID: 26534836
[TBL] [Abstract][Full Text] [Related]
13. ARHI (DIRAS3)-mediated autophagy-associated cell death enhances chemosensitivity to cisplatin in ovarian cancer cell lines and xenografts.
Washington MN; Suh G; Orozco AF; Sutton MN; Yang H; Wang Y; Mao W; Millward S; Ornelas A; Atkinson N; Liao W; Bast RC; Lu Z
Cell Death Dis; 2015 Aug; 6(8):e1836. PubMed ID: 26247722
[TBL] [Abstract][Full Text] [Related]
14. Prohibitin silencing reverses stabilization of mitochondrial integrity and chemoresistance in ovarian cancer cells by increasing their sensitivity to apoptosis.
Gregory-Bass RC; Olatinwo M; Xu W; Matthews R; Stiles JK; Thomas K; Liu D; Tsang B; Thompson WE
Int J Cancer; 2008 May; 122(9):1923-30. PubMed ID: 18183577
[TBL] [Abstract][Full Text] [Related]
15. Highly expressed NRSN2 is related to malignant phenotype in ovarian cancer.
Tang W; Ren A; Xiao H; Sun H; Li B
Biomed Pharmacother; 2017 Jan; 85():248-255. PubMed ID: 27908706
[TBL] [Abstract][Full Text] [Related]
16. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
[TBL] [Abstract][Full Text] [Related]
17. Inhibiting the mTOR pathway synergistically enhances cytotoxicity in ovarian cancer cells induced by etoposide through upregulation of c-Jun.
Itamochi H; Oishi T; Shimada M; Sato S; Uegaki K; Naniwa J; Sato S; Nonaka M; Terakawa N; Kigawa J; Harada T
Clin Cancer Res; 2011 Jul; 17(14):4742-50. PubMed ID: 21610153
[TBL] [Abstract][Full Text] [Related]
18. TLR4 and NFκB signaling is critical for taxol resistance in ovarian carcinoma cells.
Sun NK; Huang SL; Chang TC; Chao CC
J Cell Physiol; 2018 Mar; 233(3):2489-2501. PubMed ID: 28771725
[TBL] [Abstract][Full Text] [Related]
19. Krüppel-like factor 4 functions as a tumor suppressor in cervical carcinoma.
Yang WT; Zheng PS
Cancer; 2012 Aug; 118(15):3691-702. PubMed ID: 22170594
[TBL] [Abstract][Full Text] [Related]
20. Krüppel-like factor 4 negatively regulates β-catenin expression and inhibits the proliferation, invasion and metastasis of gastric cancer.
Zhang N; Zhang J; Shuai L; Zha L; He M; Huang Z; Wang Z
Int J Oncol; 2012 Jun; 40(6):2038-48. PubMed ID: 22407433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
